Coherus BioSciences, Inc. Quarterly Debt-to-equity in % from Q2 2015 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Coherus BioSciences, Inc. quarterly Debt-to-equity history and growth rate from Q2 2015 to Q2 2024.
  • Coherus BioSciences, Inc. Debt-to-equity for the quarter ending June 30, 2024 was -638 %, a 54% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 -638 -224 -54% Jun 30, 2024
Q1 2024 -519 +17.3 +3.22% Mar 31, 2024
Q4 2023 -399 +589 +59.6% Dec 31, 2023
Q3 2023 -402 +24.7K +98.4% Sep 30, 2023
Q2 2023 -414 -1.49K -139% Jun 30, 2023
Q1 2023 -536 -1.13K -190% Mar 31, 2023
Q4 2022 -988 -1.44K -316% Dec 31, 2022
Q3 2022 -25.1K -25.4K -7628% Sep 30, 2022
Q2 2022 1.07K +797 +290% Jun 30, 2022
Q1 2022 593 +341 +135% Mar 31, 2022
Q4 2021 457 +241 +111% Dec 31, 2021
Q3 2021 334 +101 +43.2% Sep 30, 2021
Q2 2021 275 Jun 30, 2021
Q1 2021 253 Mar 31, 2021
Q4 2020 216 Dec 31, 2020
Q3 2020 233 Sep 30, 2020
Q4 2018 1.49K +1.21K +426% Dec 31, 2018
Q3 2018 498 +184 +58.9% Sep 30, 2018
Q2 2018 354 -19.2 -5.14% Jun 30, 2018
Q1 2018 461 -647 -58.4% Mar 31, 2018
Q4 2017 284 +1.54K Dec 31, 2017
Q3 2017 313 +1.3K Sep 30, 2017
Q2 2017 374 +1.44K Jun 30, 2017
Q1 2017 1.11K -163 -12.8% Mar 31, 2017
Q4 2016 -1.26K -1.64K -428% Dec 31, 2016
Q3 2016 -984 -1.21K -533% Sep 30, 2016
Q2 2016 -1.07K -2.09K -205% Jun 30, 2016
Q1 2016 1.27K Mar 31, 2016
Q4 2015 384 Dec 31, 2015
Q3 2015 227 Sep 30, 2015
Q2 2015 1.02K Jun 30, 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.